1. Derynck R, and Miyazono K. The TGF-β Family. Cold Spring Harbor
Laboratory Press (2008).
2. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K. Two major Smad
pathways in TGF-β superfamily signalling. Genes Cells 7: 1191-1204 (2002).
3. Shi Y, and Massagué J. Mechanisms of TGF-β signaling from cell
membrane to the nucleus. Cell 113: 685-700 (2003).
4. Yamashita H, ten Dijke P, Franzen P, Miyazono K, Heldin CH.
Formation of hetero-oligomeric complexes of type I and type II receptors
for transforming growth factor-β. J Biol Chem 269: 20172-20178 (1994).
5. Hart PJ, Deep S, Taylor AB, Shu Z, Hinck CS, Hinck AP. Crystal
structure of the human TβR2 ectodomain-TGF-β3 complex. Nat Struct
Biol 9: 203-208 (2002).
6. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono
K, ten Dijke P, Kim S, Li E. Activin receptor-like kinase 1 modulates
transforming growth factor-β1 signaling in the regulation of
angiogenesis. Proc Natl Acad Sci USA 97: 2626-2631 (2000).
7. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery
C, Karlsson S, ten Dijke P. Activin receptor-like kinase (ALK)1 is an
72
antagonistic mediator of lateral TGF β /ALK5 signaling. Mol Cell 12:
817-828 (2003).
8. Qian SW, Burmester JK, Tsang ML, Weatherbee JA, Hinck AP, Ohlsen
DJ, Sporn MB, Roberts AB. Binding affinity of transforming growth
factor- β for its type II receptor is determined by the C-terminal region of
the molecule. J Biol Chem 271: 30656-30662 (1996).
9. Daopin S, Piez KA, Ogawa Y, Davies DR. Crystal structure of
transforming growth factor-β2: an unusual fold for the superfamily.
Science 257: 369-373 (1992).
10. Schlunegger MP, Grutter MG. An unusual feature revealed by the
crystal structure at 2.2 A resolution of human transforming growth
factor- β2. Nature 358: 430-434 (1992).
11. Hinck AP, Archer SJ, Qian SW, Roberts AB, Sporn MB, Weatherbee JA,
Tsang ML, Lucas R, Zhang BL, Wenker J, Torchia DA. Transforming
growth factor β1: three-dimensional structure in solution and
comparison with the X-ray structure of transforming growth factor β2.
Biochemistry 35: 8517-8534 (1996).
12. Mittl PR, Priestle JP, Cox DA, McMaster G, Cerletti N, Grutter MG. The
crystal structure of TGF-β3 and comparison to TGF-β2: implications for
receptor binding. Protein Sci 5: 1261-1271 (1996).
73
13. Kirsch T, Sebald W, Dreyer MK. Crystal structure of the BMP-2-BRIA
ectodomain complex. Nat Struct Biol 7: 492-496 (2000).
14. Greenwald J, Vega ME, Allendorph GP, Fischer WH, Vale W, Choe S. A
flexible activin explains the membrane-dependent cooperative assembly
of TGF-β family receptors. Mol Cell 15: 485-489 (2003).
15. Thompson TB, Woodruff TK, Jardetzky TS. Structures of an
ActRIIB:activin A complex reveal a novel binding mode for TGF-β
ligand:receptor interactions. EMBO J 22: 1555-1566 (2003).
16. Allendorph GP, Vale WW, Choe S. Structure of the ternary signaling
complex of a TGF-β superfamily member. Proc Natl Acad Sci USA 103:
7643-7648 (2006).
17. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M,
Miyazono K. Smad6 inhibits signalling by the TGF-β superfamily.
Nature 389: 622-626 (1997).
18. Kawabata M, Inoue H, Hanyu A, Imamura T, Miyazono K. Smad
proteins exist as monomers in vivo and undergo homo- and heterooligomerization upon activation by serine/threonine kinase receptors.
EMBO J 17: 4056-4065 (1998).
74
19. Oeda E, Oka Y, Miyazono K, Kawabata M. Interaction of Drosophila
inhibitors of apoptosis with Thick veins, a type I serine/threonine kinase
receptor for Decapentaplegic. J Biol Chem 273: 9353-9356 (1998).
20. Nishihara A, Hanai JI, Okamoto N, Yanagisawa J, Kato S, Miyazono K,
Kawabata M. Role of p300, a transcriptional coactivator, in signalling of
TGF-beta. Genes Cells. 3: 613-23 (1998).
21. Frolik CA, Wakefield LM, Smith DM, Sporn MB. Characterization of a
membrane receptor for transforming growth factor-β in normal rat
kidney fibroblasts. J Biol Chem 259: 10995-11000 (1984).
22. Lopez-Casillas F, Wrana JL, Massagué J. Betaglycan presents ligand to
the TGFβ signaling receptor. Cell 73: 1435-1444 (1993).
23. Ebisawa T, Tada K, Kitajima I, Tojo K, Sampath TK, Kawabata M,
Miyazono K, Imamura T. Characterization of bone morphogenetic
protein-6 signaling pathways in osteoblast differentiation. J Cell Sci 112:
3519-3527 (1999).
24. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and
computational approaches to estimate solubility and permeability in
drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26
(2001).
75
25. Ewing T. (ed). DOCK Version 4.0 Reference Manual. University of
California at San Francisco (UCSF): San Francisco, Online version
(1998).
http://www.cmpharm.ucsf.edu/kuntz/dock.html
26. Wieser R, Attisano L, Wrana JL, Massagué J. Signaling activity of
transforming growth factor beta type II receptors lacking specific
domains in the cytoplasmic region. Mol Cell Biol. 13: 7239-47 (1993).
27. Wrana JL, Attisano L, Cárcamo J, Zentella A, Doody J, Laiho M, Wang
XF, Massagué J. TGF beta signals through a heteromeric protein kinase
receptor complex. Cell. 71: 1003-14 (1992).
28. De Crescenzo G, Hinck CS, Shu Z, Zuniga J, Yang J, Tang Y, Baardsnes
J, Mendoza V, Sun L, Lopez-Casillas F, O'Connor-McCourt M, Hinck AP.
Three key residues underlie the differential affinity of the
TGFβ isoforms for the TGFβ type II receptor. J Mol Biol 355: 47-62
(2006).
29. Kim, Y. W., Park, J., Lee, H. J., Lee, S. Y., Kim, S. J. TGF-beta
sensitivity is determined by N-linked glycosylation of the type II TGFbeta receptor. Biochem J 445: 403-411 (2012).
30. Radaev S, Zou Z, Huang T, Lafer EM, Hinck AP, and Sun PD. Ternary
complex of transforming growth factor-beta1 reveals isoform-specific
76
ligand recognition and receptor recruitment in the superfamily. J Biol
Chem 285: 14806-14814 (2010).
31. Ge R, Rajeev V, Subramanian G, Reiss KA, Liu D, Higgins L, Joly A,
Dugar S, Chakravarty J, Henson M, McEnroe G, Schreiner G, Reiss M.
Selective inhibitors of type I receptor kinase block cellular transforming
growth factor-beta signaling. Biochem Pharmacol. 68 :41-50 (2004).
32. Zhang Y, Feng XH, Derynck R. Smad3 and Smad4 cooperate with cJun/c-Fos to mediate TGF-beta-induced transcription. Nature. 394: 90913 (1998).
33. Cárcamo J, Zentella A, Massagué J. Disruption of transforming growth
factor beta signaling by a mutation that prevents transphosphorylation
within the receptor complex. Mol Cell Biol. 15: 1573-81 (1995).
34. Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol. 13 :61630 (2012).
35. Birt DF, Bresnick E. Chemoprevention by non-nutrient components of
vegetables and fruits: Cancer and Nutrition. Alfin-Slater RB and
Kritchevsky D (eds). Plenum Press: New York, pp. 221-260 (1990).
36. De Azevedo WF, Jr., Mueller-Dieckmann HJ, Schulze-Gahmen U,
Worland PJ, Sausville E, Kim SH. Structural basis for specificity and
77
potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc
Natl Acad Sci USA 93: 2735-2740 (1996).
37. Senderowicz AM. Flavopiridol: the first cyclin-dependent kinase
inhibitor in human clinical trials. Invest New Drugs 17: 313-320 (1999).
38. Kelland LR. Flavopiridol, the first cyclin-dependent kinase inhibitor to
enter the clinic: current status. Expert Opin Investig Drugs 9: 2903-2911
(2000).
39. Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P, Werner J,
Perkins P, Stoltz M, Kelsen D. Phase II study of the cyclin-dependent
kinase inhibitor flavopiridol administered to patients with advanced
gastric carcinoma. J Clin Oncol 19: 1985-1992 (2001).
40. Hsiang CY, Wu SL, Ho TY. Morin inhibits 12-O-tetradecanoylphorbol-13acetate-induced hepatocellular transformation via activator protein 1
signaling pathway and cell cycle progression. Biochem Pharmacol 69:
1603-1611 (2005).
41. Lee HS, Jung KH, Hong, SW, Park IS, Lee C, Han HK, Lee DH, and
Hong SS. Morin protects acute liver damage by carbon tetracloride
(CCl(4)) in rat. Arch Pharm Res 31: 1160-1165 (2008).
78
42. Lee HS, Jung KH., Park IS., Kwon SW, Lee DH, and Hong SS.
Protective effect of morin on dimethylnitrosamine-induced hepatic
fibrosis in rats. Dig Dis Sci 54: 782-788 (2009).
43. MadanKumar P, NaveenKumar P, Devaraj H, and NiranjaliDevaraj S.
Morin, a dietary flavonoid, exhibits anti-fibrotic effect and induces
apoptosis of activated hepatic stellate cells by suppressing canonical NFkappaB signaling. Biochimie 110: 107-11 (2015).
44. Heeba GH, and Mahmoud ME. Therapeutic potential of morin against
liver fibrosis in rats: modulation of oxidative stress, cytokine production
and nuclear factor kappa B. Environ Toxicol Pharmacol 37: 662-671
(2014).
45. Perumal N, Perumal M, Halagowder D, and Sivasithamparam N. Morin
attenuates diethylnitrosamine-induced rat liver fibrosis and hepatic
stellate cell activation by co-ordinated regulation of Hippo/Yap and TGFβ1/Smad signaling. Biochimie 140: 10-19 (2017).
46. Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X. Story BM, Cornell
JE, Pollock BH., Mundy GR, and Sun LZ. Inhibition of pulmonary and
skeletal metastasis by a transforming growth factor-beta type I receptor
kinase inhibitor. Cancer Res 66: 6714-6721 (2006).
79
47. Tojo M, Hamashima Y, Hanyu A, Kajimoto T, Saitoh M, Miyazono K,
Node M, Imamura T. The ALK-5 Inhibitor A-83-01 inhibits Smad
signaling and epithelial-to-mesenchymal transition by transforming
growth factor-β. Cancer Sci 96: 791-800 (2005).
48. Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S,
Nakerakanti S, York M, Farina G, Whitfield ML, Spiera RF, Christmann
RB, Gordon JK, Weinberg J, Simms RW, and Lafyatis R. Fresolimumab
treatment decreases biomarkers and improves clinical symptoms in
systemic sclerosis patients. J Clin Invest 125: 2795-2807 (2015).
49. Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J,
Clawson DK, Britt KS, Anderson BD, Beight DW, Desaiah D, Lahn MM,
Benhadji KA, Lallena MJ, Holmgaard RB, Xu X, Zhang F, Manro JR,
Iversen PW, Iyer CV, Brekken RA, Kalos MD, Driscoll KE. Preclinical
assessment of galunisertib (LY2157299 monohydrate), a first-in-class
transforming growth factor-β receptor type I inhibitor. Oncotarget 9:
6659-6677 (2018).
50. Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler
HR, Chinot O, Cher L, Steinbach JP, Capper D, Specenier P, Rodon J,
Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Lahn
MM, and Wick W. A Phase II randomized study of galunisertib
80
monotherapy or galunisertib plus lomustine compared with lomustine
monotherapy in patients with recurrent glioblastoma. Neuro Oncol 18:
1146-1156 (2016).
51. Lan, Y., D. Zhang, C. Xu, K. W. Hance, B. Marelli, J. Qi, H. Yu, G. Qin, A.
Sircar, V. M. Hernandez, M. H. Jenkins, R. E. Fontana, A. Deshpande,
G. Locke, H. Sabzevari, L. Radvanyi and K. M. Lo. Enhanced preclinical
antitumor activity of M7824, a bifunctional fusion protein
simultaneously targeting PD-L1 and TGF-beta. Sci Transl Med 10: 424
(2018).
52. Martin, C. J., A. Datta, C. Littlefield, A. Kalra, C. Chapron, S. Wawersik,
K. B. Dagbay, C. T. Brueckner, A. Nikiforov, F. T. Danehy, Jr., F. C.
Streich, Jr., C. Boston, A. Simpson, J. W. Jackson, S. Lin, N. Danek, R.
R. Faucette, P. Raman, A. D. Capili, A. Buckler, G. J. Carven and T.
Schurpf. Selective inhibition of TGFbeta1 activation overcomes primary
resistance to checkpoint blockade therapy by altering tumor immune
landscape. Sci Transl Med 12:536 (2020).
53. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos
A, Sham PC, Li MJ, Wang J, Cardon LR, Whittaker JC, Sanseau P. The
support of human genetic evidence for approved drug indications. Nat
Genet 47: 856-60 (2015).
81
54. Hurle MR, Nelson MR, Agarwal P, Cardon LR. Trial watch: Impact of
genetically supported target selection on R&D productivity. Nat Rev
Drug Discov 15: 596-7 (2016).
55. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G,
Pangalos MN. Lessons learned from the fate of AstraZeneca's drug
pipeline: a five-dimensional framework. Nat Rev Drug Discov 13: 419-31
(2014).
82
83
謝辞
長きにわたり、多大なるご指導、ご鞭撻を賜りました東京大学大学院医学系
研究科
病因・病理学専攻
医学研究科
分子病理学分野
分子病態医学講座
宮園浩平教授、愛媛大学大学院
今村健志教授に心より感謝の意を表します。
pCAG 20-1 および pUHD 10-3 puro ベクターを供与いただいた T Era、DR
変異型 Mv1Lu 細胞を分与いただいた M. Laiho 博士と J. Massagué 博士に深
く感謝の意を表します。
84
...
論文の公開元へ
